fremanezumab has completed phase iii trials and is under review by the fda to prevent migraine and
.
.
.: "evidence for decreased calcitonin gene-related peptide (cgrp) receptors and compromised responsiveness to cgrp of fetoplacental vessels in preeclamptic pregnancies."